Efficacy and Safety of Cilostazol-Based Triple Antiplatelet Therapy Compared with Clopidogrel-Based Dual Antiplatelet Therapy in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Multicenter, Randomized, Open-Label, Phase 4 Trial
Soohyung Park,Seung-Woon Rha,Byoung Geol Choi,Woohyeun Kim,Woong Gil Choi,Seung Jin Lee,Jae Beom Lee,Ji Young Park,Sang Min Park,Myung Ho Jeong,Yong Hoon Kim,Ae-Young Her,Min Woong Kim,Kang-Yin Chen,Bae Keun Kim,Eun-Seok Shin,Jae-Bin Seo,Jihun Ahn,Se Yeon Choi,Jae Kyeong Byun,Jin Ah Cha,Su Jin Hyun,Cheol Ung Choi,Chang Gyu Park,Soo Jin Hyun
DOI: https://doi.org/10.1016/j.ahj.2023.06.015
IF: 5.099
2023-07-05
American Heart Journal
Abstract:Background : Previous studies reported that compared to conventional dual antiplatelet therapy (DAT; aspirin + clopidogrel), triple antiplatelet therapy (TAT), involving the addition of cilostazol to DAT, had better clinical outcomes in patients with ST-elevation myocardial infarction (STEMI). However, the optimal duration of TAT is yet to be determined. Methods : In total, 985 patients with STEMI who underwent primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) were prospectively enrolled in 15 PCI centers in South Korea and China. We randomly assigned patients into three groups: DAT (aspirin and clopidogrel for 12 months), TAT 1M (aspirin, clopidogrel, and cilostazol for 1 month), and TAT 6M (aspirin, clopidogrel, and cilostazol for 6 months). The primary endpoint was 1-year major adverse cardiovascular events (MACEs), defined as a composite of all-cause death, recurrent myocardial infarction, stroke, or repeat revascularization. Results : The primary endpoint did not differ among the three groups (8.8% in DAT, 11.0% in TAT 1M, and 11.6% in TAT 6M; hazard ratio for TAT 1M vs. DAT, 1.302; 95% confidence interval [CI], 0.792–2.141; p=0.297; hazard ratio for TAT 6M vs. DAT, 1.358; 95% CI, 0.829–2.225; p=0.225). With respect to in-hospital outcomes, more bleeding events occurred in the TAT group than in the DAT group (1.3% vs. 4.7% vs. 2.6%, p=0.029), with no significant differences in major bleeding events. Additionally, the TAT group had a higher incidence of headaches (0% vs. 1.6% vs. 2.6%, p=0.020). Conclusions : The addition of cilostazol to DAT did not reduce the incidence of 1-year MACEs compared with DAT alone. Instead, it may be associated with an increased risk of drug intolerance and side effects, including in-hospital bleeding and headaches.
cardiac & cardiovascular systems